-
Ultimovacs Announces NIPU Trial Design Poster Presented at World Conference of Lung Cancer Singapore 2020
-
Securities Regulation of 29 June 2007 (“STA”) – Disclosure of Significant Shareholding
-
Financial calendar
-
Ultimovacs ASA: Mandatory notification of trade by primary insider
-
Ultimovacs ASA: Mandatory notification of trade by primary insider
-
Ultimovacs ASA: Mandatory notification of trade by primary insider
-
Ultimovacs – Announces Phase II DOVACC Collaboration Study in Ovarian Cancer with the Nordic Society of Gynaecological Oncology – Clinical Trial Unit, the European Network of Gynaecological Oncological Trial Groups and AstraZeneca
-
Shareholder Notification: Ultimovacs ASA
-
Ultimovacs ASA – Initiates FOCUS Phase II Trial for Universal Cancer Vaccine, UV1, in Head and Neck Cancer Patients Receiving Pembrolizumab
-
Ultimovacs ASA – Announces Positive 5-Year Overall Survival Update from Phase I Combination Trial Evaluating Universal Cancer Vaccine UV1 in Metastatic Melanoma
